Adicet Bio Stock (NASDAQ:ACET)
Previous Close
$0.90
52W Range
$0.81 - $3.77
50D Avg
$1.19
200D Avg
$1.51
Market Cap
$70.89M
Avg Vol (3M)
$586.83K
Beta
1.70
Div Yield
-
ACET Company Profile
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
ACET Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CGEM | Cullinan Oncology, Inc. |
| TNYA | Tenaya Therapeutics, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| ALEC | Alector, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| KROS | Keros Therapeutics, Inc. |
| VOR | Vor Biopharma Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| GLUE | Monte Rosa Therapeutics, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| IGMS | IGM Biosciences, Inc. |
| AGIO | Agios Pharmaceuticals, Inc. |
| NKTX | Nkarta, Inc. |
| BCYC | Bicycle Therapeutics plc |
| AADI | Aadi Bioscience, Inc. |